Benjamin Lopez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Benjamin Lopez has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Guillaume Lefèvre
INSERM, U1286‐INFINITE‐Institute for Translational Research in Inflammation CHU Lille, Université de Lille Lille France
5 shared publications - Myriam Labalette
CHU Lille, Institut d'immunologie, Lille, France
5 shared publications - Sylvain Dubucquoi
Institut d’Immunologie, Pôle de Biologie Pathologie Génétique Médicale, CHU Lille, F-59000 Lille, France
5 shared publications - David Launay
CHU de Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des Maladies Auto-Immunes et Auto-inflammatoires Systémiques rares de l'Adulte du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France
4 shared publications - Mathilde Bahuaud
Plateforme d'Immunomonitoring Vaccinal, Laboratoire d'Immunologie, Groupe hospitalier Cochin-Broca-Hotel Dieu, Assistance Publique Hôpitaux de Paris, Paris, France
4 shared publications Adrien Hertault
Université de Lille, INSERM, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France; Vascular Surgery, CH Valenciennes, Valenciennes, France
3 shared publications
Latest Publications
- 1 September 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (9) , 1360-1370.e2
Outcomes of Preventive Embolization of the Inferior Mesenteric Artery during Endovascular Abdominal Aortic Aneurysm Repair
- 1 September 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (9) , 1360-1370.e2
Outcomes of Preventive Embolization of the Inferior Mesenteric Artery during Endovascular Abdominal Aortic Aneurysm Repair
- 1 September 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 91, 45-52
Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases
- 1 September 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 91, 45-52
Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases
- Open Access
- 15 October 2019
- Published by Croatian Society for Medical Biochemistry and Laboratory Medicine in Biochemia Medica
- Vol. 29 (3) , 559-569
Classical pathway activity C3c, C4 and C1-inhibitor protein reference intervals determination in EDTA plasma
Classical pathway activity C3c, C4 and C1-inhibitor protein reference intervals determination in EDTA plasma
- 15 October 2019
- Published by Croatian Society for Medical Biochemistry and Laboratory Medicine in Biochemia Medica
- Vol. 29 (3) , 559-569
Open AccessClassical pathway activity C3c, C4 and C1-inhibitor protein reference intervals determination in EDTA plasma
Classical pathway activity C3c, C4 and C1-inhibitor protein reference intervals determination in EDTA plasma
- 26 July 2018
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 56 (8) , 1319-1327
Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite® reagents
Background: Immunoglobulin G (IgG) and IgG subclass assays are indicated in patients with suspected primary immunodeficiency (PID). Commercially available assays for IgG subclass determination are calibrated against various preparations, and so specific reference values are required for each of them. Using Optilite® reagents from The Binding Site Group Ltd., we sought to determine the pediatric IgG and IgG subclass reference intervals with respect to the ERM-DA470k certified reference material. Methods: Levels of IgG and IgG subclasses were analyzed in serum samples collected from a large cohort of PID-free children and adolescents. Reference intervals were calculated for previously published age groups (6–12 months, 12–18 months, 18 months–2 years, 2–3 years, 3–4 years, 4–6 years, 6–9 years, 9–12 years and 12–18 years), according to the Clinical and Laboratory Standards Institute’s C28-A3c protocol. Results: A total of 456 serum samples were analyzed. The correlation between the total IgG and the sum of the IgG subclasses was good (r2=0.96). No statistically significant gender-specific differences were observed. Our results for the changes over time in IgG and IgG subclass levels are consistent with previous reports. The differences between our lower/upper reference limits and those in the literature are probably due to variations in calibration. Conclusions: Our present results provide a reliable basis for the diagnosis of PIDs in childhood and for the accreditation of laboratories using Optilite® immunoturbidimetric reagents for IgG subclass measurement. Laboratory scientists and clinicians should be aware of the need for manufacturer-specific IgG subclass reference intervals.
- 26 July 2018
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 56 (8) , 1319-1327
Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite® reagents
Background: Immunoglobulin G (IgG) and IgG subclass assays are indicated in patients with suspected primary immunodeficiency (PID). Commercially available assays for IgG subclass determination are calibrated against various preparations, and so specific reference values are required for each of them. Using Optilite® reagents from The Binding Site Group Ltd., we sought to determine the pediatric IgG and IgG subclass reference intervals with respect to the ERM-DA470k certified reference material. Methods: Levels of IgG and IgG subclasses were analyzed in serum samples collected from a large cohort of PID-free children and adolescents. Reference intervals were calculated for previously published age groups (6–12 months, 12–18 months, 18 months–2 years, 2–3 years, 3–4 years, 4–6 years, 6–9 years, 9–12 years and 12–18 years), according to the Clinical and Laboratory Standards Institute’s C28-A3c protocol. Results: A total of 456 serum samples were analyzed. The correlation between the total IgG and the sum of the IgG subclasses was good (r2=0.96). No statistically significant gender-specific differences were observed. Our results for the changes over time in IgG and IgG subclass levels are consistent with previous reports. The differences between our lower/upper reference limits and those in the literature are probably due to variations in calibration. Conclusions: Our present results provide a reliable basis for the diagnosis of PIDs in childhood and for the accreditation of laboratories using Optilite® immunoturbidimetric reagents for IgG subclass measurement. Laboratory scientists and clinicians should be aware of the need for manufacturer-specific IgG subclass reference intervals.
- 1 March 2018
- Published by Elsevier in Laboratory Investigation
- Vol. 31 (3) , 452-462
Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis
- 1 March 2018
- Published by Elsevier in Laboratory Investigation
- Vol. 31 (3) , 452-462
Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis
- Open Access
- 20 December 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 1862
Value of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies
Background: An overall response assay [OVA, based on a 23-valent pneumococcal polysaccharide vaccine (PPV23)] is widely used to screen for anti-pneumococcal antibodies. Given the heterogeneity of response from one polysaccharide (PS) to another, a World Health Organization-standardized serotype-specific enzyme-linked immunosorbent assay (SSA) is considered to be the only reliable method for testing anti-PS antibody responses in individuals with suspected primary immunodeficiencies (PIDs). Objective: To evaluate the OVA relative to the reference SSA. Methods: Serum samples of adult patients referred for a suspected PID were collected before and then 4–8 weeks after immunization with PPV23. The anti-pneumococcal response was systematically assessed with an SSA (7–16 serotypes) and interpreted according to the American Academy of Asthma, Allergy and Immunology’s current guidelines. We used receiver operating characteristic curves and agreement indices to assess the OVA’s diagnostic value in a first cohort. In order to validate these findings, a second (validation) cohort was then prospectively included. Results: Sixty-two adult patients were included, and 42 (67.7%) were defined as poor responders according to the SSA. Only the post-immunization titer in the OVA was able to correctly identify poor responders; a titer below 110 mg/L gave a positive predictive value of 100% [identifying 24 (57.1%) of the 42 poor responders], and similar levels of diagnostic performance were observed in the validation cohort. The pre-vaccination antibody titer, the post/pre-vaccination antibody titer ratio and a post-vaccination titer above 110 mg/L in the OVA were not predictive of the response in the SSA. Conclusion: A post-vaccination antibody titer below 110 mg/L in the OVA was constantly associated with a poor PPV23 response using the SSA. In all other cases, SSA is the only reliable method for assessing diagnostic vaccination with PPV23.
- 20 December 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 1862
Open AccessValue of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies
Background: An overall response assay [OVA, based on a 23-valent pneumococcal polysaccharide vaccine (PPV23)] is widely used to screen for anti-pneumococcal antibodies. Given the heterogeneity of response from one polysaccharide (PS) to another, a World Health Organization-standardized serotype-specific enzyme-linked immunosorbent assay (SSA) is considered to be the only reliable method for testing anti-PS antibody responses in individuals with suspected primary immunodeficiencies (PIDs). Objective: To evaluate the OVA relative to the reference SSA. Methods: Serum samples of adult patients referred for a suspected PID were collected before and then 4–8 weeks after immunization with PPV23. The anti-pneumococcal response was systematically assessed with an SSA (7–16 serotypes) and interpreted according to the American Academy of Asthma, Allergy and Immunology’s current guidelines. We used receiver operating characteristic curves and agreement indices to assess the OVA’s diagnostic value in a first cohort. In order to validate these findings, a second (validation) cohort was then prospectively included. Results: Sixty-two adult patients were included, and 42 (67.7%) were defined as poor responders according to the SSA. Only the post-immunization titer in the OVA was able to correctly identify poor responders; a titer below 110 mg/L gave a positive predictive value of 100% [identifying 24 (57.1%) of the 42 poor responders], and similar levels of diagnostic performance were observed in the validation cohort. The pre-vaccination antibody titer, the post/pre-vaccination antibody titer ratio and a post-vaccination titer above 110 mg/L in the OVA were not predictive of the response in the SSA. Conclusion: A post-vaccination antibody titer below 110 mg/L in the OVA was constantly associated with a poor PPV23 response using the SSA. In all other cases, SSA is the only reliable method for assessing diagnostic vaccination with PPV23.
- 9 October 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (4) , 637-638
Reply to Gilchrist et al. and to Musher
To the Editor—We read with interest Gilchrist and colleagues’ report of an adult case of recurrent bacterial meningitis, presenting with both an immunodeficiency and a local promoting factor. The patient first presented with a history of 2 episodes of pneumococcal meningitis in 3 years and then an episode of meningococcal meningitis 6 years later, despite antibiotic prophylaxis (the details of which were not provided) and protein-conjugate vaccination (probably against Streptococcus pneumoniae). After the first 2 episodes, immunological evaluation detected an IgG2 subclass deficiency and associated poor anti-pneumococcal antibody responses. Surprisingly, an initial computed tomography (CT) scan did not find any skull base abnormalities after the 2 episodes of pneumococcal meningitis. However, dehiscence of the right tegmen tympani was observed after the episode of meningococcal meningitis—suggesting a...
- 9 October 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (4) , 637-638
Reply to Gilchrist et al. and to Musher
To the Editor—We read with interest Gilchrist and colleagues’ report of an adult case of recurrent bacterial meningitis, presenting with both an immunodeficiency and a local promoting factor. The patient first presented with a history of 2 episodes of pneumococcal meningitis in 3 years and then an episode of meningococcal meningitis 6 years later, despite antibiotic prophylaxis (the details of which were not provided) and protein-conjugate vaccination (probably against Streptococcus pneumoniae). After the first 2 episodes, immunological evaluation detected an IgG2 subclass deficiency and associated poor anti-pneumococcal antibody responses. Surprisingly, an initial computed tomography (CT) scan did not find any skull base abnormalities after the 2 episodes of pneumococcal meningitis. However, dehiscence of the right tegmen tympani was observed after the episode of meningococcal meningitis—suggesting a...
- 1 August 2017
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 23 (8) , 576.e1-576.e5
Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection
- 1 August 2017
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 23 (8) , 576.e1-576.e5
Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection
- 13 April 2017
- Published by Springer Nature in Surgical Endoscopy
- Vol. 31 (11) , 4705-4710
A plea for thoracoscopic resection of solitary pulmonary nodule in cancer patients
Solitary pulmonary nodules (SPN) are frequently detected in cancer patients. These lesions are often considered as pulmonary metastases and increasingly treated by non-surgical techniques without histological confirmation. The aim of this study is to determine the histological nature of SPN resected by thoracoscopy and to identify risk factors of malignancy.
- 13 April 2017
- Published by Springer Nature in Surgical Endoscopy
- Vol. 31 (11) , 4705-4710
A plea for thoracoscopic resection of solitary pulmonary nodule in cancer patients
Solitary pulmonary nodules (SPN) are frequently detected in cancer patients. These lesions are often considered as pulmonary metastases and increasingly treated by non-surgical techniques without histological confirmation. The aim of this study is to determine the histological nature of SPN resected by thoracoscopy and to identify risk factors of malignancy.
- 1 April 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 65 (2) , 328-331
Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases
We report on 11 cases of specific polysaccharide antibody deficiency (SPAD) revealed in adulthood by severe infections with encapsulated bacteria. Given that immunoglobulin replacement therapy can effectively prevent the recurrence of bacterial infections in this context, SPAD should be considered once other antibody deficiencies have been ruled out.
- 1 April 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 65 (2) , 328-331
Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases
We report on 11 cases of specific polysaccharide antibody deficiency (SPAD) revealed in adulthood by severe infections with encapsulated bacteria. Given that immunoglobulin replacement therapy can effectively prevent the recurrence of bacterial infections in this context, SPAD should be considered once other antibody deficiencies have been ruled out.